| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Quiflapon sodium (formerly known as L-686,70 sodium and MK591 sodium) is a novel, potent, selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 1.6 nM in a FLAP binding assay. MK-0591 had no effect on rat 5-lipoxygenase. MK-0591 has a high affinity for 5-lipoxygenase activating protein (FLAP) as evidenced by an IC50 value of 1.6 nM in a FLAP binding assay and inhibition of the photoaffinity labelling of FLAP by two different photoaffinity ligands. Inhibition of activation of 5-lipoxygenase was shown through inhibition of the translocation of the enzyme from the cytosol to the membrane in human PMNLs. MK-0591 was a potent inhibitor of LT biosynthesis in vivo, first, following ex vivo challenge of blood obtained from treated rats and squirrel monkeys, second, in a rat pleurisy model, and, third, as monitored by inhibition of the urinary excretion of LTE4 in antigen-challenged allergic sheep. Inhibition of antigen-induced bronchoconstriction by MK-0591 was observed in inbred rats pretreated with methysergide, Ascaris-challenged squirrel monkeys, and Ascaris-challenged sheep (early and late phase response). These results indicate that MK-0591 is a potent inhibitor of LT biosynthesis both in vitro and in vivo indicating that the compound will be suitable for assessing the role of leukotrienes in pathological situations.
| ln Vitro |
SB203580 and Quiflaponodium (MK591) prevent human PBMC cells from proliferating when exposed to SEB. Three genes that are increased by SEB—cathepsin L, IL-17, and guanylate binding protein (GBP)-2—are downregulated by quilaponodium (MK591) [1]. Treatment with quiflapon sodium (MK591) causes apoptosis within hours. Additionally, quilaponodium causes the stress kinase c-Jun N-terminal kinase (JNK) to activate quickly. JNK is crucial to the process of apoptosis. Prostate cancer cells undergo apoptosis when exposed to quilapon sodium, however PI3K-Akt or ERK are not inhibited. Furthermore, Quifflapon sodium and LY294002 work in concert to cause prostate cancer cells to undergo apoptosis [2]. Sp1 is unaffected by quilapon sodium (MK591), but the cAMP response element binding protein is[4].
|
|---|---|
| ln Vivo |
In contrast to the untreated hyperoxia group, the mice in the hyperoxia group given Quiflapon sodium (MK591) (20, 40 mg/kg) demonstrated aberrant alveolarization, while the alveolarization in the treated group resembled that of room air controls. However, no inflammation is present [3]. When Aβ immunopositive areas from placebo and Quiflapon sodium (MK591) (320 mg/kg) treatment groups were compared, the treated mice's amyloid load was statistically significantly lower. Moreover, quilapon sodium dramatically lowers brain levels of IL-1β. The steady-state levels of overall CREB and its Ser133 phosphorylated version were statistically significantly lower in mice given Quiflapon sodium [4].
|
| References |
[1]. Mendis C, et al. Effect of 5-lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells. FEBS J. 2008 Jun;275(12):3088-98.
[2]. Sarveswaran S, et al. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett. 2010 May 28;291(2):167-76. [3]. Park MS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung. 2011 Feb;189(1):43-50. [4]. Chu J, et al. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation. 2012 Jun 14;9:127 |
| Molecular Formula |
C34H34N2O3SCL-.NA+
|
|---|---|
| Molecular Weight |
609.15316
|
| CAS # |
147030-01-1
|
| Related CAS # |
Quiflapon;136668-42-3
|
| SMILES |
O=C(C(C)(CC(N1CC2=CC=C(C=C2)Cl)=C(C3=C1C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3)SC(C)(C)C)C)O[Na]
|
| InChi Key |
YPURUCMVRRNPHJ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C34H35ClN2O3S.Na/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39;/h6-18H,19-21H2,1-5H3,(H,38,39);/q;+1/p-1
|
| Chemical Name |
sodium 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate
|
| Synonyms |
MK 0591 sodium; MK-0591; MK0591; L 686708; L-686,708; MK 591; MK591; MK-591
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~82.08 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6416 mL | 8.2082 mL | 16.4163 mL | |
| 5 mM | 0.3283 mL | 1.6416 mL | 3.2833 mL | |
| 10 mM | 0.1642 mL | 0.8208 mL | 1.6416 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA